5-[ 123I]iodo-A-85380

Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects

Masashi Ueda, Yasuhiko Iida, Takahiro Mukai, Marcelo Mamede, Koichi Ishizu, Mikako Ogawa, Yasuhiro Magata, Junji Konishi, Hideo Saji

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recently, 5-[ 123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([ 123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [ 123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [ 123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4% of the injected dose and this value gradually decreased with time. The majority (∼75%) of the radioactivity was excreted in urine within 24 hr, and less than 1% remained in all organs tested. The biological half-life of [ 123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [ 123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [ 123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.

Original languageEnglish
Pages (from-to)337-344
Number of pages8
JournalAnnals of Nuclear Medicine
Volume18
Issue number4
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Radiometry
Nicotinic Receptors
Single-Photon Emission-Computed Tomography
Neuroimaging
Healthy Volunteers
Pharmacology
Safety
Radioactivity
Radiation
Brain
Urinary Bladder
Ligands
No-Observed-Adverse-Effect Level
Body Image
Half-Life
Gastrointestinal Tract
Software
5-iodo-3-(2-azetidinylmethoxy)pyridine
Urine
Kidney

Keywords

  • 5-[ I]iodo-3-(2(S)-azetidinylmethoxy)pyridine
  • Nicotinic acetylcholine receptor
  • Pharmacological effects
  • Radiation dosimetry
  • Single photon emission computed tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

5-[ 123I]iodo-A-85380 : Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. / Ueda, Masashi; Iida, Yasuhiko; Mukai, Takahiro; Mamede, Marcelo; Ishizu, Koichi; Ogawa, Mikako; Magata, Yasuhiro; Konishi, Junji; Saji, Hideo.

In: Annals of Nuclear Medicine, Vol. 18, No. 4, 06.2004, p. 337-344.

Research output: Contribution to journalArticle

Ueda, M, Iida, Y, Mukai, T, Mamede, M, Ishizu, K, Ogawa, M, Magata, Y, Konishi, J & Saji, H 2004, '5-[ 123I]iodo-A-85380: Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects', Annals of Nuclear Medicine, vol. 18, no. 4, pp. 337-344.
Ueda, Masashi ; Iida, Yasuhiko ; Mukai, Takahiro ; Mamede, Marcelo ; Ishizu, Koichi ; Ogawa, Mikako ; Magata, Yasuhiro ; Konishi, Junji ; Saji, Hideo. / 5-[ 123I]iodo-A-85380 : Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. In: Annals of Nuclear Medicine. 2004 ; Vol. 18, No. 4. pp. 337-344.
@article{b827266c436a4719baa3b769b60cf52d,
title = "5-[ 123I]iodo-A-85380: Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects",
abstract = "Recently, 5-[ 123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([ 123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [ 123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [ 123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4{\%} of the injected dose and this value gradually decreased with time. The majority (∼75{\%}) of the radioactivity was excreted in urine within 24 hr, and less than 1{\%} remained in all organs tested. The biological half-life of [ 123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [ 123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [ 123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.",
keywords = "5-[ I]iodo-3-(2(S)-azetidinylmethoxy)pyridine, Nicotinic acetylcholine receptor, Pharmacological effects, Radiation dosimetry, Single photon emission computed tomography",
author = "Masashi Ueda and Yasuhiko Iida and Takahiro Mukai and Marcelo Mamede and Koichi Ishizu and Mikako Ogawa and Yasuhiro Magata and Junji Konishi and Hideo Saji",
year = "2004",
month = "6",
language = "English",
volume = "18",
pages = "337--344",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - 5-[ 123I]iodo-A-85380

T2 - Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects

AU - Ueda, Masashi

AU - Iida, Yasuhiko

AU - Mukai, Takahiro

AU - Mamede, Marcelo

AU - Ishizu, Koichi

AU - Ogawa, Mikako

AU - Magata, Yasuhiro

AU - Konishi, Junji

AU - Saji, Hideo

PY - 2004/6

Y1 - 2004/6

N2 - Recently, 5-[ 123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([ 123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [ 123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [ 123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4% of the injected dose and this value gradually decreased with time. The majority (∼75%) of the radioactivity was excreted in urine within 24 hr, and less than 1% remained in all organs tested. The biological half-life of [ 123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [ 123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [ 123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.

AB - Recently, 5-[ 123I]iodo-3-(2(S)-azetidinylmethoxy)pyridine ([ 123I]5IA) was developed as a ligand for imaging the nicotinic acetylcholine receptor (nAChR) in human brain using single photon emission computed tomography (SPECT). In the present study, the toxicity and radiation absorbed dose of [ 123I]5IA were investigated. Behavior and physiological parameters were examined in mice and rats after administration of 5IA. There were no changes in these parameters in animals administered 1 μg/kg of 5IA or less, indicating that the no observed effect level (NOEL) of 5IA was 1 μg/kg. [ 123I]5IA was then administered to healthy human subjects and serial whole-body images were acquired over 24 hr. Initially, high levels of radioactivity were observed in the liver and urinary bladder and moderate levels in the lungs, kidneys, and brain. Whole brain activity at 1 hr was 4.6 ± 0.4% of the injected dose and this value gradually decreased with time. The majority (∼75%) of the radioactivity was excreted in urine within 24 hr, and less than 1% remained in all organs tested. The biological half-life of [ 123I]5IA averaged 7.2 ± 4.0 hr. Based on the biodistribution data, radiation absorbed doses were estimated using MIRDOSE 3.1 software with the dynamic bladder model and the ICRP gastrointestinal (GI) tract model. Consequently, the effective dose equivalent was estimated to be 30 ± 1.4 μSv/MBq, which is an acceptable radiation burden. Having determined the safety of this compound, we performed SPECT imaging in a healthy human subject using 171 MBq of [ 123I]5IA. SPECT images clearly revealed a cerebral distribution of radioactivity that was consistent with the known distribution of central nAChRs in humans. These results suggest that [ 123I]5IA is a promising ligand for imaging nAChRs in humans, with an acceptable dosimetry and pharmacological safety at the dose required for adequate SPECT imaging.

KW - 5-[ I]iodo-3-(2(S)-azetidinylmethoxy)pyridine

KW - Nicotinic acetylcholine receptor

KW - Pharmacological effects

KW - Radiation dosimetry

KW - Single photon emission computed tomography

UR - http://www.scopus.com/inward/record.url?scp=4143054599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143054599&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 337

EP - 344

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 4

ER -